Oxybutynin 5 mg tabs — $0 with Membership
Oxybutynin 5 mg tabs has an active canonical formulary match. No-additional-cost pricing is subject to its listed supply, quantity, fill, and fulfillment limits.
Oxybutynin 5 mg tabs Pricing
| Pricing type | Price |
|---|---|
| TheDrugClub | $0 with membership |
| Typical Retail | $49.00 |
Free with membership subject to the listed formulary limits.
About Oxybutynin 5 mg tabs
Oxybutynin 5 mg tabs is a prescription medication. Ask your doctor if Oxybutynin 5 mg tabs is right for you.
Other strengths and forms of Oxybutynin
Conditions Treated with Oxybutynin 5 mg tabs
How to Check Oxybutynin 5 mg tabs Pricing
- Join TheDrugClub for $19.95/month
- Receive your member card by email
- Present your card at a participating pharmacy
- Check active-formulary eligibility or available membership pricing
Oxybutynin 5 mg tabs at Participating Pharmacies
- CVS Pharmacy
- Walgreens
- Walmart Pharmacy
- Rite Aid
- Kroger Pharmacy
- Costco Pharmacy
- Albertsons
- Safeway
- Publix Pharmacy
- H-E-B Pharmacy
Pharmacy participation and fulfillment options vary. Present your membership card and confirm current pricing before filling.
Related medications
Other medications associated with the same conditions in this catalog.
Also listed for Overactive Bladder / Urge Incontinence
What Oxybutynin 5 mg tabs is approved for (FDA label)
Oxybutynin chloride tablets are indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria).
Source: Read the full FDA label on DailyMed. Label effective date: July 27, 2026.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Adverse reactions for Oxybutynin 5 mg tabs (FDA label)
The safety and efficacy of oxybutynin chloride was evaluated in a total of 199 patients in three clinical trials. These participants were treated with oxybutynin chloride 5 to 20 mg/day for up to 6 weeks. Table 3 shows the incidence of adverse events judged by investigators to be at least possibly related to treatment and reported by at least 5% of patients. The most common adverse events reported by patients receiving oxybutynin chloride 5 to 20 mg/day were the expected side effects of anticholinergic agents. The incidence of dry mouth was dose-related. In addition, the following adverse events were reported by 1 to < 5% of patients using oxybutynin chloride (5 to 20 mg/day) in all studies.
Source: FDA prescribing information (DailyMed). Set ID: 7c497c6c-2448-2c80-e053-2991aa0ab8c7. SPL document ID: 57a1be6c-ccda-bbd3-e063-6394a90a34d8. Label effective date: July 27, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Contraindications for Oxybutynin 5 mg tabs (FDA label)
Oxybutynin chloride is contraindicated in patients with urinary retention, gastric retention and other severe decreased gastrointestinal motility conditions, uncontrolled narrow-angle glaucoma and in patients who are at risk for these conditions. Oxybutynin chloride is also contraindicated in patients who have demonstrated hypersensitivity to the drug substance or other components of the product.
Source: FDA prescribing information (DailyMed). Set ID: 7c497c6c-2448-2c80-e053-2991aa0ab8c7. SPL document ID: 57a1be6c-ccda-bbd3-e063-6394a90a34d8. Label effective date: July 27, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Warnings and precautions for Oxybutynin 5 mg tabs (FDA label)
WARNINGS Angioedema of the face, lips, tongue and/or larynx has been reported with oxybutynin. In some cases, angioedema occurred after the first dose. Angioedema associated with upper airway swelling may be life-threatening. If involvement of the tongue, hypopharynx, or larynx occurs, oxybutynin should be promptly discontinued and appropriate therapy and/or measures necessary to ensure a patent airway should be promptly provided.
Source: FDA prescribing information (DailyMed). Set ID: 7c497c6c-2448-2c80-e053-2991aa0ab8c7. SPL document ID: 57a1be6c-ccda-bbd3-e063-6394a90a34d8. Label effective date: July 27, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Drug interactions for Oxybutynin 5 mg tabs (FDA label)
The concomitant use of oxybutynin with other anticholinergic drugs or with other agents which produce dry mouth, constipation, somnolence (drowsiness), and/or other anticholinergic-like effects may increase the frequency and/or severity of such effects. Anticholinergic agents may potentially alter the absorption of some concomitantly administered drugs due to anticholinergic effects on gastrointestinal motility. This may be of concern for drugs with a narrow therapeutic index. Anticholinergic agents may also antagonize the effects of the prokinetic agents, such as metoclopramide. Mean oxybutynin chloride plasma concentrations were approximately 3 to 4 fold higher when oxybutynin chloride was administered with ketoconazole, a potent CYP3A4 inhibitor. Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., C max and AUC). The clinical relevance of such potential interactions is not known.
Source: FDA prescribing information (DailyMed). Set ID: 7c497c6c-2448-2c80-e053-2991aa0ab8c7. SPL document ID: 57a1be6c-ccda-bbd3-e063-6394a90a34d8. Label effective date: July 27, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.